Contrasting GH Research (NASDAQ:GHRS) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX)

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Profitability

This table compares RegeneRx Biopharmaceuticals and GH Research’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RegeneRx Biopharmaceuticals	N/A	N/A	N/A
GH Research	N/A	-15.48%	-15.01%

Risk & Volatility

RegeneRx Biopharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Institutional and Insider Ownership

56.9% of GH Research shares are held by institutional investors. 12.6% of RegeneRx Biopharmaceuticals shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares RegeneRx Biopharmaceuticals and GH Research’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RegeneRx Biopharmaceuticals	$80,000.00	0.03	-$1.73 million	N/A	N/A
GH Research	N/A	N/A	-$35.59 million	($0.68)	-15.46

RegeneRx Biopharmaceuticals has higher revenue and earnings than GH Research.

Analyst Ratings

This is a summary of current ratings and recommmendations for RegeneRx Biopharmaceuticals and GH Research, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RegeneRx Biopharmaceuticals	0	0	0	0	N/A
GH Research	0	0	2	0	3.00

GH Research has a consensus price target of $39.50, indicating a potential upside of 275.83%. Given GH Research’s higher possible upside, analysts clearly believe GH Research is more favorable than RegeneRx Biopharmaceuticals.

Summary

RegeneRx Biopharmaceuticals beats GH Research on 5 of the 9 factors compared between the two stocks.

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.